[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651283":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":26,"responsibleParty":39,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Indolent Systemic Mastocytosis Cohort",null,"Adults aged 18 years and older with a diagnosis of indolent systemic mastocytosis who meet eligibility criteria will complete prospective symptom, electronic patient reported outcomes (ePRO), quality of life (QOL) assessments, wearable, environmental exposure, and biospecimen collection over the study period.",[13],{"name":14,"affiliation":5,"role":15},"Thanai Pongdee, MD","PRINCIPAL_INVESTIGATOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Laurie Mulhern","CONTACT","507-284-8160","Mulhern.Laurie@mayo.edu",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Kay Bachman","507-284-5689","Bachman.Kay@mayo.edu",[27],{"facility":5,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Rochester","Minnesota","55905","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-92.4699,44.02163,{"lat":37,"lon":36},{"type":15,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Thanai Pongdee","Principal Investigator","100651283","precision-medicine-for-indolent-systemic-mastocytosis-prism-100651283",false,"NCT07757893","Precision Medicine for Indolent Systemic Mastocytosis (PRISM)","PRISM","Inclusion Criteria:\n\n* Diagnosis of indolent systemic mastocytosis as defined by the World Health Organization 2022 criteria.\n* Doses of baseline treatment medications are stable for ≥ 14 days prior to enrollment.\n* Patient must have an Eastern Cooperative Oncology Group Performance Status of 0 to 2.\n\nExclusion Criteria:\n\n* Diagnosis of advanced systemic mastocytosis defined by established criteria as outlined by the World Health Organization 2022 criteria.\n* Patient must not have had any cytoreductive therapy including but not limited to cladribine, interferon alpha, pegylated interferon, or antibody therapy \\\u003C 28 days prior to enrollment.\n* Any other significant medical issue as determined by the principal investigator.","ALL","18 Years",{"count":52,"type":53},25,"ESTIMATED","OBSERVATIONAL","This study is being done to better understand how symptoms of Systemic Mastocytosis (SM) relate to biological signals and to better understand how different treatments affect these signals.",[57],"Systemic Mastocytosis","NOT_YET_RECRUITING","2026-08-14",{"date":61,"type":62},"2026-08-18","ACTUAL",{"date":64,"type":53},"2026-09-09",{"date":66,"type":53},"2027-08-31",{"name":5,"class":6},1]